Sugen's TK Angiogenesis Inhibitors

- Sugen's FLK-1 tyrosine kinase receptor blockers can inhibit angiogenesis and solid tumor growth, according to a new study published in Cancer Research (August 1). The small-molecule blockers inhibited the formation of blood vessels in response to stimulation with vascular endothelial growth factor. This is an important development for Sugen, providing further evidence of the validity of its TK inhibitor approach, as it continues its preclinical program to define suitable lead candidates for clinical testing.